A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Stopped early

Conditions studied: Breast Cancer

In brief

The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. To date no other trial has analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, the researchers expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. Rather, the researchers expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.

Key facts

Study ID

NCT00235235

Run by

Hoosier Cancer Research Network

People needed

80

Starts

2005-09-01

Expected to finish

2010-12-01

Last updated by the study team

2015-12-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease.
• Disease amenable to pre-treatment core or incisional biopsy with adequate tissue for histology and genomic/proteomic analysis.
• Measurable disease as assessed within 21 days prior to being registered for protocol therapy by RECIST.
• Planned chemotherapy with one of the following regimens:
• Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
• Capecitabine 1000 mg/m2 BID days 1-14 of every 21-day cycle
• Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
• Gemcitabine 1000 mg/m2 days 1, 8, 15 of every 28-day cycle

You may not qualify if…

• No serious uncontrolled medical or surgical condition that the investigator feels might compromise study participation.
• Negative pregnancy test obtained within 7 days prior to being registered for protocol therapy for women of child bearing potential.
• Unwillingness to use adequate contraception (or practicing complete abstinence). Subjects should be advised that adequate contraception (or complete abstinence) must be continued while on treatment and for a period of 3 months after the final dose of chemotherapy.
• No breast-feeding.

Where it is running

• Cancer Care Center of Southern Indiana — Bloomington, Indiana, United States
• Fort Wayne Oncology & Hematology, Inc — Fort Wayne, Indiana, United States
• Center for Cancer Care at Goshen Health System — Goshen, Indiana, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Mary Lou Mayer, M.D. — Indianapolis, Indiana, United States
• Community Regional Cancer Center — Indianapolis, Indiana, United States
• Arnett Cancer Care — Lafayette, Indiana, United States
• Horizon Oncology Center — Lafayette, Indiana, United States
• Northern Indiana Cancer Research Consortium — South Bend, Indiana, United States
• Baylor College of Medicine - Methodist Breast Center — Houston, Texas, United States
• Instituto de Enfermedades Neoplasticas (INEN) — Lima, Peru

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.